Lenalidomide 191732-72-6

98% up, USP/BP

Product categories

New Products

Product Details

Product Information

Product name	Lenalidomide
CAS No.	191732-72-6
Molecular Formula	C13H13N3O3
Molecular Weight	259.26062
Quality Standard	98% up, Medicine Grade
Appearance	White to light yellow crystalline powder

COA of Lenalidomide

Test Items	Specifications	Results
Appearance	White to light yellow crystalline powder	conforms
Water content	≤ 4.0%	0.021
Residuce on ignition	≤ 0.5%	0.0032
Residual Solvents	Methanol≤ 3000ppm	1400ppm
	Acetonitrile≤ 410ppm	not detected
	Carbon tetrachloride≤ 4ppm	not detected
	Tetrahydrofuran≤ 720ppm	250ppm
	Dimethylformamide	320ppm
	≤ 550ppm
Related Substance	Single Impurity≤1%	0.004
	Total Impurity≤1.5%	0.008
Assay	≥98.0%	0.996
Test Items	Specifications	Results
Appearance	White to light yellow crystalline powder	conforms
Water content	≤ 4.0%	0.021
Residuce on ignition	≤ 0.5%	0.0032
Residual Solvents	Methanol≤ 3000ppm	1400ppm
	Acetonitrile≤ 410ppm	not detected
	Carbon tetrachloride≤ 4ppm	not detected
	Tetrahydrofuran≤ 720ppm	250ppm
	Dimethylformamide	320ppm
	≤ 550ppm
Related Substance	Single Impurity≤1%	0.004
	Total Impurity≤1.5%	0.008
Assay	≥98.0%	99.6%

Usage

Function of Lenalidomide

1. Lenalidomide API is an anti-tumor drug developed by Celgene biopharmaceutical company. The chemical structure is similar to thalidomide, which has multiple functions such as anti-tumor, immune regulation and anti-angiogenesis.

2. Lenalidomide inhibits the secretion of proinflammatory cytokines and increases the secretion of anti-inflammatory cytokines in peripheral blood monocytes.

3. Lenalidomide can also inhibit the expression of cyclooxygenase 2(cox-2), but it has no effect on cox-1.

4. Lenalidomide besides can be used to treat MDS and MM, for multiple myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized the degeneration amylum and with marrow unripe systemic bone marrow fibrosis disease have certain curative effect.

5. Lenalidomide is currently the most effective drug to treat multiple myeloma.

*Products under the patent are only for R&D use